Olaparib (AZD2281, Ku-0059436)

Catalog No.S1060

Molecular Weight(MW): 434.46

Olaparib (AZD2281, KU0059436) is a selective inhibitor of PARP1/2 with IC50 of 5 nM/1 nM in cell-free assays, 300-times less effective against tankyrase-1.

Cited by 349 Publications

Cancer Discov, 2019, 9(6):722-737

PubMed: 31015319 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Cancer Cell, 2019, 35(3):519-533

PubMed: 30889383 ( click the link to review the publication )

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Cancer Cell, 2019, 35(5):752-766

PubMed: 31085176 ( click the link to review the publication )

Nature, 2018, 555(7696):387-391

PubMed: 29513652 ( click the link to review the publication )

Nature, 2018, 560(7716):112-116

PubMed: 30022158 ( click the link to review the publication )

Nature, 2018, 560(7716):117-121

PubMed: 30022168 ( click the link to review the publication )

Cell, 2018, 173(4):972-988

PubMed: 29656893 ( click the link to review the publication )

Cell, 2018, 172(1-2):373-386

PubMed: 29224780 ( click the link to review the publication )

Nat Genet, 2018, 50(8):1086-1092

PubMed: 30013182 ( click the link to review the publication )

Cancer Discov, 2018, 8(1):74-93

PubMed: 28923912 ( click the link to review the publication )

Cancer Discov, 2018, 8(8):988-1005

PubMed: 29880585 ( click the link to review the publication )

Cancer Cell, 2018, 33(2):202-216

PubMed: 29358035 ( click the link to review the publication )

Nature, 2017, 549(7673):548-552

PubMed: 28959974 ( click the link to review the publication )

Nature, 2017, 550(7676):360-365

PubMed: 28976962 ( click the link to review the publication )

Cell, 2017, S0092-8674(17)31437-X

PubMed: 29290468 ( click the link to review the publication )

Nature, 2015, 528(7582):422-6

PubMed: 26649820 ( click the link to review the publication )

Cell Metab, 2014, 19(6):1034-41

PubMed: 24814482 ( click the link to review the publication )

Science, 2013, 339(6120):700-4

PubMed: 23306437 ( click the link to review the publication )

Nat Methods , 2013, 10(10):981-4

PubMed: 23955771 ( click the link to review the publication )

Cancer Discov, 2012, 2(11):1036-47

PubMed: 22915752 ( click the link to review the publication )

Cell, 2011, 145(4):529-42

PubMed: 21565612 ( click the link to review the publication )

Nat Commun, 2021, 10(1):3993

PubMed: 31488816 ( click the link to review the publication )
Cell Res, 2019, 29(3):233-247

PubMed: 30728452 ( click the link to review the publication )

Mol Cell, 2019, 73(5):885-899

PubMed: 30686591 ( click the link to review the publication )

Mol Cell, 2019, 75(6):1286-1298

PubMed: 31473101 ( click the link to review the publication )

Mol Cell, 2019, 73(4):670-683.e12

PubMed: 30639241 ( click the link to review the publication )

Nat Commun, 2019, 10(1):1307

PubMed: 30898999 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2556

PubMed: 31186408 ( click the link to review the publication )

Nat Commun, 2019, 10(1):4632

PubMed: 31604914 ( click the link to review the publication )

Nat Commun, 2019, 10(1):4363

PubMed: 31554794 ( click the link to review the publication )

Nucleic Acids Res, 2019, 47(11):5634-5647

PubMed: 31006810 ( click the link to review the publication )

Nucleic Acids Res, 2019, 10.1093/nar/gkz820

PubMed: 31566235 ( click the link to review the publication )

Clin Cancer Res, 2019, 25(20):6127-6140

PubMed: 31409614 ( click the link to review the publication )

Clin Cancer Res, 2019, 25(20):6206-6216

PubMed: 31409613 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432

PubMed: 31439587 ( click the link to review the publication )

Genes Dev, 2019, 33(5-6):333-347

PubMed: 30796017 ( click the link to review the publication )

Genes Dev, 2019, 33(19-20):1397-1415

PubMed: 31467087 ( click the link to review the publication )

Cancer Res, 2019, 79(17):4491-4502

PubMed: 31273064 ( click the link to review the publication )

Cancer Res, 2019, 10.1158/0008-5472.CAN-18-1673

PubMed: 30733193 ( click the link to review the publication )

Cancer Res, 2019, 79(8):2031-2041

PubMed: 30824588 ( click the link to review the publication )

Int J Cancer, 2019, 10.1002/ijc.32670

PubMed: 31495919 ( click the link to review the publication )

Int J Cancer, 2019, 144(7):1685-1696

PubMed: 30478958 ( click the link to review the publication )

Int J Cancer, 2019, 144(5):1092-1103

PubMed: 30152517 ( click the link to review the publication )

J Med Chem, 2019, 62(11):5330-5357

PubMed: 31042381 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):90

PubMed: 30786932 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):463

PubMed: 31718704 ( click the link to review the publication )
Pigment Cell Melanoma Res, 2019, 10.1111/pcmr.12841

PubMed: 31663663 ( click the link to review the publication )

Br J Cancer, 2019, 121(7):600-610

PubMed: 31481733 ( click the link to review the publication )

FASEB J, 2019, 33(6):6778-6788

PubMed: 30807703 ( click the link to review the publication )

Stem Cells, 2019, 37(1):42-53

PubMed: 30353615 ( click the link to review the publication )

Mol Cancer Ther, 2019, 10.1158/1535-7163

PubMed: 31534014 ( click the link to review the publication )

Mol Cancer Ther, 2019, 10.1158/1535-7163.MCT-17-0256

PubMed: 31575654 ( click the link to review the publication )

Mol Cancer Ther, 2019, 10.1158/1535-7163.MCT-17-0256

PubMed: 31575654 ( click the link to review the publication )

Mol Cancer Ther, 2019, 10.1158/1535-7163.MCT-19-0242

PubMed: 31534014 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(8):1439-1450

PubMed: 31142662 ( click the link to review the publication )

Mol Cancer Ther, 2019, 10.1158/1535-7163.MCT-19-0474

PubMed: 31597711 ( click the link to review the publication )

Transl Res, 2019, 10.1016/j.trsl.2019.10.003

PubMed: 31707040 ( click the link to review the publication )

Am J Cancer Res, 2019, 9(3):608-618

PubMed: 30949414 ( click the link to review the publication )

Mol Cancer Res, 2019, 17(2):431-445

PubMed: 30401718 ( click the link to review the publication )

Mol Cancer Res, 2019, 17(1):42-53

PubMed: 30201826 ( click the link to review the publication )

Lung Cancer, 2019, 135:56-65

PubMed: 31447003 ( click the link to review the publication )

Cancer Sci, 2019, 110(3):1064-1075

PubMed: 30663191 ( click the link to review the publication )

Biochem Pharmacol, 2019, 10.1016/j.bcp.2019.06.022

PubMed: 31251940 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(19)

PubMed: 31554189 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(19)

PubMed: 31554189 ( click the link to review the publication )

J Biol Chem, 2019, 294(33):12459-12471

PubMed: 31248990 ( click the link to review the publication )

J Biol Chem, 2019, 294(2):397-404

PubMed: 30478172 ( click the link to review the publication )

Mol Carcinog, 2019, 58(10):1770-1782

PubMed: 31219654 ( click the link to review the publication )

Mol Carcinog, 2019, 58(10):1770-1782

PubMed: 31219654 ( click the link to review the publication )

Breast Cancer Res Treat, 2019, 176(1):109-117

PubMed: 30989461 ( click the link to review the publication )
Mediators Inflamm, 2019, 2019:1656484

PubMed: 31178661 ( click the link to review the publication )

Invest New Drugs, 2019, 10.1007/s10637-018-00717-9

PubMed: 30612311 ( click the link to review the publication )

Virology, 2019, 537:254-262

PubMed: 31539774 ( click the link to review the publication )

Prostate, 2019, 79(4):390-402

PubMed: 30520109 ( click the link to review the publication )

Cell Cycle, 2019, 1-14

PubMed: 31238782 ( click the link to review the publication )

BMC Cancer, 2019, 19(1):829

PubMed: 31438892 ( click the link to review the publication )

Cancer Med, 2019, 10.1002/cam4.2528

PubMed: 31512408 ( click the link to review the publication )

Transl Oncol, 2019, 12(7):871-878

PubMed: 31075528 ( click the link to review the publication )

J Gynecol Oncol, 2019, 30(2):e26

PubMed: 30740957 ( click the link to review the publication )

PLoS One, 2019, 14(10):e0223725

PubMed: 31596905 ( click the link to review the publication )

PLoS One, 2019, 14(11):e0221288

PubMed: 31721781 ( click the link to review the publication )

PLoS One, 2019, 14(8):e0213130

PubMed: 31408463 ( click the link to review the publication )

PLoS One, 2019, 14(8):e0213130

PubMed: 31408463 ( click the link to review the publication )

Biochem Biophys Res Commun, 2019, 508(2):620-625

PubMed: 30522863 ( click the link to review the publication )

Biochem Biophys Res Commun, 2019, 10.1016/j.bbrc.2019.11.050

PubMed: 31753490 ( click the link to review the publication )

Biochem Biophys Res Commun, 2019, 510(4):501-507

PubMed: 30737031 ( click the link to review the publication )

Leuk Lymphoma, 2019, 60(4):1098-1101

PubMed: 30277116 ( click the link to review the publication )

Mol Cell Biochem, 2019, 457(1-2):41-49

PubMed: 30993494 ( click the link to review the publication )

Mol Med Rep, 2019, 20(4):3609-3616

PubMed: 31485633 ( click the link to review the publication )

Mol Med Rep, 2019, 19(1):75-84

PubMed: 30431088 ( click the link to review the publication )

Am J Vet Res, 2019, 80(7):663-669

PubMed: 31246122 ( click the link to review the publication )

Nanomedicine (Lond), 2019, 14(17):2315-2338

PubMed: 31432749 ( click the link to review the publication )

Cell Chem Biol, 2019, 10.1016/j.chembiol.2019.10.013

PubMed: 31735695 ( click the link to review the publication )

NPJ Breast Cancer, 2019, 5:14

PubMed: 30993195 ( click the link to review the publication )
Nucleic Acids Res, 2019, 47(17):9132-9143

PubMed: 31329989 ( click the link to review the publication )

Mol Cell, 2019, 10.1016/j.molcel.2019.09.024

PubMed: 31653568 ( click the link to review the publication )

Cell Rep, 2019, 27(11):3331-3344

PubMed: 31189115 ( click the link to review the publication )

Cell Death Dis, 2019, 10(4):281

PubMed: 30911007 ( click the link to review the publication )

Nat Chem Biol, 2018, 14(9):837-840

PubMed: 30013063 ( click the link to review the publication )

J Clin Invest, 2018, 128(7):2951-2965

PubMed: 29649003 ( click the link to review the publication )

J Clin Invest, 2018, 128(7):2951-2965

PubMed: 29649003 ( click the link to review the publication )

Nat Commun, 2018, 9(1):2678

PubMed: 29992957 ( click the link to review the publication )

Nat Commun, 2018, 9(1):1849

PubMed: 29748565 ( click the link to review the publication )

Nat Commun, 2018, 9(1):176

PubMed: 29330466 ( click the link to review the publication )

Nat Commun, 2018, 9(1):2016

PubMed: 29789535 ( click the link to review the publication )

J Immunother Cancer, 2018, 6(1):133

PubMed: 30486888 ( click the link to review the publication )

Cell Rep, 2018, 24(13):3393-3403

PubMed: 30257201 ( click the link to review the publication )

Cell Rep, 2018, 25(8):2061-2069

PubMed: 30463005 ( click the link to review the publication )

Cell Rep, 2018, 23(11):3127-3136

PubMed: 29898385 ( click the link to review the publication )

Cell Rep, 2018, 24(10):2629-2642

PubMed: 30184498 ( click the link to review the publication )

Elife, 2018, 10.7554/eLife.37818

PubMed: 30088474 ( click the link to review the publication )

Elife, 2018, 10.7554/eLife.38771

PubMed: 29985131 ( click the link to review the publication )

Elife, 2018, 10.7554/eLife.29747

PubMed: 29313488 ( click the link to review the publication )

Cancer Lett, 2018, 423:60-70

PubMed: 29526801 ( click the link to review the publication )

J Exp Clin Cancer Res, 2018, 37(1):129

PubMed: 29954437 ( click the link to review the publication )

Cancers (Basel), 2018, 10(5)

PubMed: 29783721 ( click the link to review the publication )

Cancers (Basel), 2018, 10(5)

PubMed: 29783721 ( click the link to review the publication )

PLoS Pathog, 2018, 14(11):e1007394

PubMed: 30395643 ( click the link to review the publication )
Br J Cancer, 2018, 119(11):1392-1400

PubMed: 30425352 ( click the link to review the publication )

Arch Toxicol, 2018, 92(2):759-775

PubMed: 28975372 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(6):1167-1176

PubMed: 29626126 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(10):2206-2216

PubMed: 29970481 ( click the link to review the publication )

Mol Oncol, 2018, 12(4):561-576

PubMed: 29465803 ( click the link to review the publication )

Mol Oncol, 2018, 12(4):561-576

PubMed: 29465803 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(3):428-438

PubMed: 29222170 ( click the link to review the publication )

Int J Nanomedicine, 2018, 13:8063-8074

PubMed: 30555227 ( click the link to review the publication )

Biochem Pharmacol, 2018, 10.1016/j.bcp.2018.10.011

PubMed: 30342021 ( click the link to review the publication )

Biochem Pharmacol, 2018, 150:24-34

PubMed: 29355504 ( click the link to review the publication )

Am J Cancer Res, 2018, 8(9):1837-1846

PubMed: 30323975 ( click the link to review the publication )

Biomed Pharmacother, 2018, 101:719-728

PubMed: 29524880 ( click the link to review the publication )

J Pharmacol Exp Ther, 2018, 365(1):117-126

PubMed: 29339456 ( click the link to review the publication )

Cancer Biol Ther, 2018, 19(9):797-808

PubMed: 29923797 ( click the link to review the publication )

Cancer Med, 2018, 7(4):1285-1296

PubMed: 29479816 ( click the link to review the publication )

Oncol Rep, 2018, 39(5):2261-2269

PubMed: 29512738 ( click the link to review the publication )

Oncol Rep, 2018, 40(1):479-487

PubMed: 29767248 ( click the link to review the publication )

PLoS One, 2018, 13(3):e0194611

PubMed: 29590171 ( click the link to review the publication )

PLoS One, 2018, 13(11):e0207399

PubMed: 30444904 ( click the link to review the publication )

PLoS One, 2018, 13(1):e0190717

PubMed: 29298345 ( click the link to review the publication )

PLoS One, 2018, 13(12):e0207934

PubMed: 30543656 ( click the link to review the publication )

Head Neck, 2018, 40(8):1676-1684

PubMed: 29570891 ( click the link to review the publication )

Anal Biochem, 2018, 543:132-139

PubMed: 29247608 ( click the link to review the publication )

Blood Cells Mol Dis, 2018, 71:23-28

PubMed: 29422232 ( click the link to review the publication )
Nat Commun, 2018, 9(1):697

PubMed: 29449575 ( click the link to review the publication )

Oncotarget, 2018, 9(47):28456-28473

PubMed: 29983873 ( click the link to review the publication )

Oncotarget, 2018, 9(88):35844-35855

PubMed: 30533199 ( click the link to review the publication )

Cell Rep, 2018, 25(8):2061-2069

PubMed: 30463005 ( click the link to review the publication )

Oncotarget, 2018, 9(99):37319-37332

PubMed: 30647872 ( click the link to review the publication )

DNA Repair (Amst), 2018, 68:12-24

PubMed: 29807321 ( click the link to review the publication )

Oncotarget, 2018, 9(98):37080-37096

PubMed: 30647846 ( click the link to review the publication )

J Exp Clin Cancer Res, 2018, 37(1):129

PubMed: 29954437 ( click the link to review the publication )

Cancer Cell, 2018, 33(3):401-416

PubMed: 29533782 ( click the link to review the publication )

Biochem Biophys Rep, 2018, 16:115-121

PubMed: 30417129 ( click the link to review the publication )

Blood, 2017, 130(26):2848-2859

PubMed: 29042365 ( click the link to review the publication )

Mol Cell, 2017, 65(5):900-916

PubMed: 28238654 ( click the link to review the publication )

Mol Cell, 2017, 66(5):622-634

PubMed: 28575658 ( click the link to review the publication )

Nat Struct Mol Biol, 2017, 24(9):734-742

PubMed: 28805810 ( click the link to review the publication )

Nat Protoc, 2017, 12(9):1951-1961

PubMed: 28837130 ( click the link to review the publication )

Nucleic Acids Res, 2017, 45(7):3906-3921

PubMed: 28160604 ( click the link to review the publication )

J Thorac Oncol, 2017, 12(8):1309-1319

PubMed: 28389374 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(2):514-522

PubMed: 28034904 ( click the link to review the publication )

Genes Dev, 2017, 31(1):46-58

PubMed: 28115467 ( click the link to review the publication )

Elife, 2017, 10.7554/eLife.30523

PubMed: 29106372 ( click the link to review the publication )

Oncogene, 2017, 36(33):4682-4691

PubMed: 28394338 ( click the link to review the publication )

Cancer Lett, 2017, 398:1-11

PubMed: 28385602 ( click the link to review the publication )

Cancer Lett, 2017, 386:131-140

PubMed: 27894958 ( click the link to review the publication )

J Exp Clin Cancer Res, 2017, 36(1):63

PubMed: 28482906 ( click the link to review the publication )
Cell Death Dis, 2017, 8(1):e2526

PubMed: 28055012 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(9):1934-1941

PubMed: 28522591 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(12):2892-2901

PubMed: 28958991 ( click the link to review the publication )

Mol Cancer Ther, 2017, 10.1158/1535-7163.MCT-16-0740

PubMed: 28500233 ( click the link to review the publication )

Mol Oncol, 2017, 11(5):470-490

PubMed: 28173629 ( click the link to review the publication )

Mol Cancer Res, 2017, 15(1):45-58

PubMed: 27671334 ( click the link to review the publication )

Sci Rep, 2017, 7(1):12876

PubMed: 28993682 ( click the link to review the publication )

Virology, 2017, 507:220-230

PubMed: 28456021 ( click the link to review the publication )

Cancer Biol Ther, 2017, 18(9):694-704

PubMed: 28886275 ( click the link to review the publication )

Cell Cycle, 2017, 16(11):1128-1135

PubMed: 28463527 ( click the link to review the publication )

Transl Oncol, 2017, 10(2):190-196

PubMed: 28182994 ( click the link to review the publication )

Oncol Res, 2017, 25(9):1441-1451

PubMed: 28429680 ( click the link to review the publication )

PLoS One, 2017, 12(9):e0184619

PubMed: 28886188 ( click the link to review the publication )

PLoS One, 2017, 12(9):e0184619

PubMed: 28886188 ( click the link to review the publication )

Leuk Lymphoma, 2017, 58(11):2705-2716

PubMed: 28394191 ( click the link to review the publication )

Biochem Biophys Res Commun, 2017, 488(1):211-217

PubMed: 28487110 ( click the link to review the publication )

Int J Med Sci, 2017, 14(12):1292-1300

PubMed: 29104487 ( click the link to review the publication )

Mol Med Rep, 2017, 16(1):208-214

PubMed: 28498459 ( click the link to review the publication )

Oncotarget, 2017, 8(53):90662-90673

PubMed: 29207595 ( click the link to review the publication )

Oncotarget, 2017, 8(8):13223-13239

PubMed: 28099939 ( click the link to review the publication )

Tumour Biol, 2017, 39(10):1010428317713390

PubMed: 29064327 ( click the link to review the publication )

Oncotarget, 2017, 8(40):68707-68720

PubMed: 28978150 ( click the link to review the publication )

Oncotarget, 2017, 8(67):111026-111040

PubMed: 29340034 ( click the link to review the publication )

Oncotarget, 2017, 8(53):90842-90851

PubMed: 29207607 ( click the link to review the publication )
Oncotarget, 2017, 8(53):90842-90851

PubMed: 29207607 ( click the link to review the publication )

Oncotarget, 2017, 8(55):94505-94518

PubMed: 29212245 ( click the link to review the publication )

Oncotarget, 2017, 8(18):29963-29975

PubMed: 28415784 ( click the link to review the publication )

Blood Adv, 2017, 1(19):1467-1472

PubMed: 29296788 ( click the link to review the publication )

Oncotarget, 2017, 8(61):103931-103951

PubMed: 29262611 ( click the link to review the publication )

Genes Dev, 2017, 31(3):318-332

PubMed: 28242626 ( click the link to review the publication )

Oncotarget, 2017, 8(25):40152-40168

PubMed: 27374179 ( click the link to review the publication )

Nat Cell Biol, 2016, 18(12):1357-1366

PubMed: 27820601 ( click the link to review the publication )

Blood, 2016, 127(1):139-48

PubMed: 26463424 ( click the link to review the publication )

Nat Struct Mol Biol, 2016, 23(7):647-55

PubMed: 27239795 ( click the link to review the publication )

Nucleic Acids Res, 2016, 45(5):2546-2557

PubMed: 27965414 ( click the link to review the publication )

Cancer Res, 2016, 76(9):2778-90

PubMed: 27197267 ( click the link to review the publication )

Theranostics, 2016, 6(11):1821-32

PubMed: 27570553 ( click the link to review the publication )

Cell Rep, 2016, 17(9):2367-2381

PubMed: 27880910 ( click the link to review the publication )

Elife, 2016, 10.7554/eLife.13620

PubMed: 27336789 ( click the link to review the publication )

J Invest Dermatol, 2016, 136(6):1219-1228

PubMed: 26880244 ( click the link to review the publication )

Diabetologia, 2016, 59(11):2360-2368

PubMed: 27539148 ( click the link to review the publication )

Br J Cancer, 2016, 114(7):777-86

PubMed: 26964031 ( click the link to review the publication )

Bioinformatics, 2016, 32(12):i253-i261

PubMed: 27307624 ( click the link to review the publication )

Gynecol Oncol, 2016, 142(2):323-31

PubMed: 27282964 ( click the link to review the publication )

DNA Repair , 2016, 10.1016/j.dnarep.2016.06.001

PubMed: 27373144 ( click the link to review the publication )

Sci Rep, 2016, 6:19567

PubMed: 26777522 ( click the link to review the publication )

Analyst, 2016, 141(8):2454-62

PubMed: 26974179 ( click the link to review the publication )

Analyst, 2016, 141(8):2454-62

PubMed: 26974179 ( click the link to review the publication )
Mediators Inflamm, 2016, 2016:1984703

PubMed: 27524861 ( click the link to review the publication )

Cell Cycle, 2016, 15(22):3105-3114

PubMed: 27686740 ( click the link to review the publication )

BMC Cancer, 2016, 16:621

PubMed: 27515310 ( click the link to review the publication )

BMC Cancer, 2016, 16(1):851

PubMed: 27816051 ( click the link to review the publication )

BMC Cancer, 2016, 16(1):725

PubMed: 27613518 ( click the link to review the publication )

BMC Cancer, 2016, 16:550

PubMed: 27465688 ( click the link to review the publication )

Eur J Pharmacol, 2016, 791:444-454

PubMed: 27612628 ( click the link to review the publication )

Bioorg Med Chem, 2016, 24(5):1071-8

PubMed: 26833244 ( click the link to review the publication )

Neurochem Res, 2016, 41(7):1516-26

PubMed: 26869042 ( click the link to review the publication )

PLoS One, 2016, 11(1):e0146031

PubMed: 26730949 ( click the link to review the publication )

Biochem Biophys Res Commun, 2016, 478(1):234-240

PubMed: 27425251 ( click the link to review the publication )

Anal Biochem, 2016, 503:58-64

PubMed: 27036617 ( click the link to review the publication )

Nucl Med Biol, 2016, 43(12):752-758

PubMed: 27689533 ( click the link to review the publication )

Nucl Med Biol, 2016, 43(12):752-758

PubMed: 27689533 ( click the link to review the publication )

Target Oncol, 2016, 11(5):655-665

PubMed: 27188390 ( click the link to review the publication )

Oncotarget, 2016, 7(7):7701-14

PubMed: 26713604 ( click the link to review the publication )

Oncotarget, 2016, 7(12):13984-4001

PubMed: 26910887 ( click the link to review the publication )

Int J Radiat Oncol Biol Phys, 2016, 95(2):772-81

PubMed: 27020103 ( click the link to review the publication )

Oncotarget, 2016, 7(9):9732-41

PubMed: 26799421 ( click the link to review the publication )

Zhongguo Fei Ai Za Zhi, 2016, 19(1):16-23

PubMed: 26805733 ( click the link to review the publication )

Oncotarget, 2016, 7(22):32980-9

PubMed: 27145275 ( click the link to review the publication )

Oncotarget, 2016, 7(46):75551-75560

PubMed: 27705909 ( click the link to review the publication )

Nanoscale, 2015, 7(6):2805-11

PubMed: 25584654 ( click the link to review the publication )

Oncogene, 2015, 10.1038/onc.2015.212

PubMed: 26073085 ( click the link to review the publication )
Oncogene, 2015, 10.1038/onc.2014.443

PubMed: 25619829 ( click the link to review the publication )

Mol Cancer Ther, 2015, 10.1158/1535-7163.MCT-14-0810

PubMed: 25777962 ( click the link to review the publication )

Mol Cancer Ther, 2015, 14(5):1236-46

PubMed: 25777962 ( click the link to review the publication )

Front Oncol, 2015, 5:191

PubMed: 26380221 ( click the link to review the publication )

J Transl Med, 2015, 13:239

PubMed: 26198537 ( click the link to review the publication )

J Transl Med, 2015, 13:225

PubMed: 26169874 ( click the link to review the publication )

J Transl Med, 2015, 13:233

PubMed: 26183824 ( click the link to review the publication )

Sci Rep, 2015, 5:11465

PubMed: 26095524 ( click the link to review the publication )

Front Microbiol, 2015, 6:878

PubMed: 26379653 ( click the link to review the publication )

Biochem J, 2015, 469(2):189-98

PubMed: 25940138 ( click the link to review the publication )

Int J Oncol, 2015, 47(1):262-8

PubMed: 25975349 ( click the link to review the publication )

Cancer Discov, 2015, 5(7):752-67

PubMed: 26069190 ( click the link to review the publication )

Cell Cycle, 2015, 14(20):3261-9

PubMed: 26317799 ( click the link to review the publication )

Cell Cycle, 2015, 14(20):3248-60

PubMed: 26312527 ( click the link to review the publication )

BMC Cancer, 2015, 15:89

PubMed: 25884663 ( click the link to review the publication )

BMC Cancer, 2015, 15(1):1090

PubMed: 25777417 ( click the link to review the publication )

Drug Des Devel Ther, 2015, 9:3183-90

PubMed: 26124641 ( click the link to review the publication )

Dis Esophagus, 2015, 10.1111/dote.12299

PubMed: 25604309 ( click the link to review the publication )

Biochem Biophys Res Commun, 2015, 460(2):183-90

PubMed: 25767076 ( click the link to review the publication )

Onco Targets Ther, 2015, 8:3047-54

PubMed: 26543375 ( click the link to review the publication )

Mol Cell Biochem, 2015, 400(1-2):153-62

PubMed: 25404465 ( click the link to review the publication )

J Breast Cancer, 2015, 18(4):329-38

PubMed: 26770239 ( click the link to review the publication )

Oncol Lett, 2015, 9(2):757-761

PubMed: 25621047 ( click the link to review the publication )

Oncotarget, 2015, 6(41):43679-97

PubMed: 26544897 ( click the link to review the publication )
Oncotarget, 2015, 6(38):41307-23

PubMed: 26513298 ( click the link to review the publication )

DNA Repair (Amst), 2015, 35:106-15

PubMed: 26519824 ( click the link to review the publication )

DNA Repair (Amst), 2015, 26:23-9

PubMed: 25541391 ( click the link to review the publication )

Princeton University, 2015, 88435/dsp01br86b5821

PubMed: ( click the link to review the publication )

Cell, 2015, 161(7):1592-605

PubMed: 26052046 ( click the link to review the publication )

Nat Commun, 2014, 5:5496

PubMed: 25400221 ( click the link to review the publication )

Nat Commun, 2014, 5:3361

PubMed: 24553445 ( click the link to review the publication )

Nucleic Acids Res, 2014, 42(11):7028-38

PubMed: 24861619 ( click the link to review the publication )

Cancer Res, 2014, 74(21):5948-54

PubMed: 25145669 ( click the link to review the publication )

Cell Rep, 2014, 8(6):1808-18

PubMed: 25199834 ( click the link to review the publication )

Cell Death Differ, 2014, 21(2):258-69

PubMed: 24121277 ( click the link to review the publication )

Eur J Cancer, 2014, 50(15):2725-34

PubMed: 25128455 ( click the link to review the publication )

Cancer Lett, 2014, 348(1-2):20-8

PubMed: 24534203 ( click the link to review the publication )

Sci Signal, 2014, 7(326):ra47

PubMed: 24847116 ( click the link to review the publication )

J Med Chem, 2014, 57(13):5579-601

PubMed: 24922587 ( click the link to review the publication )

Breast Cancer Res, 2014, 16(2):R25

PubMed: 24625110 ( click the link to review the publication )

J Cereb Blood Flow Metab, 2014, 127(23):5079-92

PubMed: 25248836 ( click the link to review the publication )

J Neuroscience, 2014, 34(28):9338-50

PubMed: 25009267 ( click the link to review the publication )

Arch Toxicol, 2014, 10.1007/s00204-014-1434-0

PubMed: 25526924 ( click the link to review the publication )

PLoS Genet, 2014, 10(10):e1004654

PubMed: 25275444 ( click the link to review the publication )

Mol Cancer Ther, 2014, 13(6):1645-54

PubMed: 24694947 ( click the link to review the publication )

Mol Cancer Ther, 2014, 13(3):724-32

PubMed: 24356817 ( click the link to review the publication )

Mol Cancer Ther, 2014, 13(6):1645-54

PubMed: 24694947 ( click the link to review the publication )

Mol Cancer Ther, 2014, 13(4):986-95

PubMed: 24552776 ( click the link to review the publication )
Mol Oncol, 2014, 10.1016/j.molonc.2014.07.022

PubMed: 25139258 ( click the link to review the publication )

Mol Oncol, 2014, S1574-7891(14)00132-X

PubMed: 25028150 ( click the link to review the publication )

Radiother Oncol, 2014, 113(3):345-51

PubMed: 25467050 ( click the link to review the publication )

Oral Oncol, 2014, 50(9):825-31

PubMed: 25017803 ( click the link to review the publication )

Cancer Sci, 2014, 105(2):202-10

PubMed: 24219164 ( click the link to review the publication )

J Cell Mol Med, 2014, 18(1):143-55

PubMed: 24238094 ( click the link to review the publication )

Biochim Biophys Acta, 2014, 1852(3):462-472

PubMed: 25483710 ( click the link to review the publication )

Biochim Biophys Acta, 2014, 1843(11):2662-2673

PubMed: 25072752 ( click the link to review the publication )

Biochim Biophys Acta, 2014, 1844(10):1765-72

PubMed: 25062913 ( click the link to review the publication )

J Trans Med, 2014, 12(1):184

PubMed: 24965603 ( click the link to review the publication )

Mol Pharmacol, 2014, 9(4):e95649

PubMed: 24748377 ( click the link to review the publication )

Int J Oncol, 2014, 44(3):735-44

PubMed: 24378347 ( click the link to review the publication )

Cell Cycle, 2014, 13(11):1708-16

PubMed: 24675890 ( click the link to review the publication )

Cell Cycle, 2014, 12(11):1679-87

PubMed: 23656790 ( click the link to review the publication )

J Pharm Sci, 2014, 103(6):1913-20

PubMed: 24700236 ( click the link to review the publication )

PLoS One, 2014, 9(9):e108731

PubMed: 25264618 ( click the link to review the publication )

J Cardiovasc Pharmacol, 2014, 10.1038/onc.2014.105

PubMed: 24769898 ( click the link to review the publication )

Medicine, 2014, 93(28):e294

PubMed: 25526472 ( click the link to review the publication )

Oncol Lett, 2014, 8(3):1222-1228

PubMed: 25120693 ( click the link to review the publication )

Oncotarget, 2014, 5(10):3023-8

PubMed: 24632590 ( click the link to review the publication )

Oncotarget, 2014, 5(10):3023-8

PubMed: 24632590 ( click the link to review the publication )

Nat Struct Mol Biol, 2013, 20(3):347-54

PubMed: 23396353 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(18):5003-15

PubMed: 23881923 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2013, 12(7):529-34

PubMed: 23684799 ( click the link to review the publication )
Cancer Res, 2013, 72(11):2814-21

PubMed: 22447567 ( click the link to review the publication )

Cancer Res, 2013, 74(1):287-97

PubMed: 24240700 ( click the link to review the publication )

Oncogene, 2013, 32(47):5377-87

PubMed: 23934192 ( click the link to review the publication )

Cancer Lett, 2013, 343(2):217-23

PubMed: 24215868 ( click the link to review the publication )

J Exp Clin Cancer Res, 2013, 32(1):95

PubMed: 24252502 ( click the link to review the publication )

FASEB J, 2013, 27(6):2316-27

PubMed: 23444429 ( click the link to review the publication )

PLoS Genet, 2013, 9(6):e1003531

PubMed: 23785295 ( click the link to review the publication )

Mol Oncol, 2013, 7(3):567-79

PubMed: 23415752 ( click the link to review the publication )

Carcinogenesis, 2013, 34(4):739-49

PubMed: 23275151 ( click the link to review the publication )

Neoplasia, 2013, 15(6):600-8

PubMed: 23730208 ( click the link to review the publication )

Mol Cancer Res, 2013, 11(10):1179-92

PubMed: 23913164 ( click the link to review the publication )

DNA Repair , 2013, 12(12):1134-42

PubMed: 24210699 ( click the link to review the publication )

J Viral Hepat, 2013, 20(9):658-65

PubMed: 23910651 ( click the link to review the publication )

J Biol Chem, 2013, 288(10):7086-95

PubMed: 23355489 ( click the link to review the publication )

Cancer Biol Ther, 2013, 14(6):537-45

PubMed: 23760496 ( click the link to review the publication )

PLoS One, 2013, 8(6):e66130

PubMed: 23762475 ( click the link to review the publication )

J Mass Spectrom, 2013, 48(12):1285-90

PubMed: 24338883 ( click the link to review the publication )

DNA Repair (Amst), 2013, 12(6):394-402

PubMed: 23570906 ( click the link to review the publication )

Hepatology, 2012, 55(6):1840-51

PubMed: 22223166 ( click the link to review the publication )

Nat Struct Mol Biol, 2012, 19(4):417-23

PubMed: 22388737 ( click the link to review the publication )

EMBO Mol Med, 2012, 4(10):1087-96

PubMed: 22933245 ( click the link to review the publication )

Oncogene, 2012, 32(39):4634-45

PubMed: 23108394 ( click the link to review the publication )

Cancer Lett, 2012, 319(2):232-41

PubMed: 22266096 ( click the link to review the publication )

J Med Chem, 2012, 55(7):3011-20

PubMed: 22380680 ( click the link to review the publication )
Neoplasia, 2012, 14(3):169-77

PubMed: 22496617 ( click the link to review the publication )

DNA Repair , 2012, 11(6):537-49

PubMed: 22542292 ( click the link to review the publication )

Cancer Sci, 2012, 103(6):1045-50

PubMed: 22404155 ( click the link to review the publication )

J Biol Chem, 2012, 287(47):39824-33

PubMed: 21956491 ( click the link to review the publication )

J Biol Chem, 2012, 287(44):36777-91

PubMed: 22961983 ( click the link to review the publication )

J Biol Chem, 2012, 287(52):43720-9

PubMed: 23105099 ( click the link to review the publication )

PLoS One, 2012, 7(6):e39956

PubMed: 22768182 ( click the link to review the publication )

Int J Radiat Oncol Biol Phys, 2012, 84(3):815-21

PubMed: 22417805 ( click the link to review the publication )

ACS Nano, 2011, 5(11):9216-24

PubMed: 21962084 ( click the link to review the publication )

J Biol Chem, 2011, 286(14):12157-65

PubMed: 21285347 ( click the link to review the publication )

Mol Cell Biol, 2011, 31(12):2462-9

PubMed: 21482670 ( click the link to review the publication )

PLoS One, 2011, 6(11):e27183

PubMed: 22073281 ( click the link to review the publication )

EMBO Rep, 2010, 11(12):962-8

PubMed: 21052091 ( click the link to review the publication )

Purity & Quality Control

Choose Selective PARP Inhibitors

Biological Activity

Description

Olaparib (AZD2281, KU0059436) is a selective inhibitor of PARP1/2 with IC50 of 5 nM/1 nM in cell-free assays, 300-times less effective against tankyrase-1.

Features

A potent PARP inhibitor (currently in late stage clinical trials).

Targets

PARP2 ^[1] (Cell-free assay)	PARP1 ^[1] (Cell-free assay)
1 nM	5 nM

In vitro

Olaparib would act against BRCA1 or BRCA2 mutations. Olaparib is not sensitive to tankyrase-1 (IC50 >1 μM). Olaparib could ablate the PARP-1 activity at concentrations of 30-100 nM in SW620 cells. Olaparib is hypersensitive to BRCA1-deficient cell lines (MDA-MB-463 and HCC1937), compared with BRCA1- and BRCA2-proficient cell lines (Hs578T, MDA-MB-231, and T47D). ^[1] Olaparib is strongly sensitive to KB2P cells due to suppression of base excision repair by PARP inhibition, which may result in the conversion of single-strand breaks to double-strand breaks during DNA replication, thus activating BRCA2-dependent recombination pathways. ^[2]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
KP3.33	NXLmU4hRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		Mm[wOEBl		NEn5XmdKSzVyPUWuO\|A2KCEQvF2g	MmXaNVg2PTl4MUO=
KP6.3	MkXSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M4PZUlQh\A>?		MU\JR\|UxRTFyLkSyPEDPxE1i	NVnuPHVSOTh3NUm2NVM>
KP7.7	NXLmcHJpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NHfa[YM1KGR?		NHOyW5JKSzVyPUW3JI5OKA>?	M4PxclE5PTV7NkGz
KB2P3.4	MofmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MUO0JIQ>		NWLFfZQzUUN3ME2xNlQhVSB?	M4HRPFE5PTV7NkGz
KB2P1.21	MmTYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NWj6XFRiPCCm		NVH6SJhIUUN3ME24PVA4KG6PIB?=	MoizNVg2PTl4MUO=
U373-MG	NF;WWFVEgXSxdH;4bYMhSXO\|YYm=	MnzhNUDPxE1i	MVKyOEBp		NH7EWoVKdmO{ZXHz[ZMhemGmaXH0bY9vKHOnboPpeIl3cXS7	NVnZU5k5OTh7NUS3NVI>
T98G	MlfrR5l1d3SxeHnjJGF{e2G7	MX[xJO69VSB?	NFnNPI0zPCCq		NV;kdI4yUW6lcnXhd4V{KHKjZHnheIlwdiC\|ZX7zbZRqfmm2eR?=	MnK1NVg6PTR5MUK=
U87-MG	NYexSFM6S3m2b4TvfIlkKEG\|c3H5	NX3aWoFDOSEQvF2g	NGm2O4szPCCq		M2TtWWlv[3KnYYPld{Bz[WSrYYTpc44he2Wwc3n0bZZqfHl?	MX[xPFk2PDdzMh?=
UVW	NWHK[GJGS3m2b4TvfIlkKEG\|c3H5	MWG1NFAhdk1?	MoP4NlQhcA>?		NFXvRmdKdmO{ZXHz[ZMhemGmaXH0bY9vKHOnboPpeIl3cXS7	NHPrU40yQDl3NEexNi=>
HeLa	M1u0TGZ2dmO2aX;uJGF{e2G7	M1TXRVUxOCCwTR?=	MoXjOEBp		NVWxVHFCS2G3c3XzJIEhdW:mZYP0JIRmdGG7IHnuJJJmcm:rbnnu[{Bw\iC{YXTpZZRqd25vaX7keYNm\CCGTlGgZpJm[Wu\|	M2j2NFE5QTV2N{Gy
HeLa	MXjGeY5kfGmxbjDBd5NigQ>?	MorVNUDPxE1i	NEe2epgzPCCq		NIXiboxGdmijbnPld{Bz[WSrYYTpc44ucW6mdXPl[EBUNXCqYYPlJIFzemW\|dB?=	NX6weY1oOTh7NUS3NVI>
T98G	M2fSWGZ2dmO2aX;uJGF{e2G7	M4C3cFEh\|ryPIB?=	NU\HOVlmOjRiaB?=		MV;FcohidmOnczDyZYRq[XSrb36tbY5lfWOnZDDTMZBp[XOnIHHydoV{fA>?	NEDrN3oyQDl3NEexNi=>
L3	NYDkXIVnS3m2b4TvfIlkKEG\|c3H5	MV[1JO69VSB?	MWG5OkBp	M3vUc2ROW09?	MWfTbYdvcW[rY3HueIx6KGmwaHnibZR{KGOnbHygd5Vzfmm4YXy=	NIfESWszODF{NES1PS=>
Granta-519	MXzDfZRwfG:6aXOgRZN{[Xl?	NI\pe3o2KM7:TTC=	NYDGNWN3QTZiaB?=	NUnp[pZXTE2VTx?=	NITz[29UdGmpaITsfUBqdmirYnn0d{Bk\WyuIIP1dpZqfmGu	M3XhRVIxOTJ2NEW5
BT	NIPvcoJEgXSxdH;4bYMhSXO\|YYm=	Mn;2OUDPxE1i	MVO5OkBp	NHfHOWtFVVOR	NGWyU4hUdGmpaITsfUBqdmirYnn0d{Bk\WyuIIP1dpZqfmGu	MV:yNFEzPDR3OR?=
UPN2	NYfCeGJVS3m2b4TvfIlkKEG\|c3H5	NV\QUI94PSEQvF2g	M3zBflk3KGh?	NEDCNFlFVVOR	M4jlcnNtcWeqdHz5JIlvcGmkaYTzJINmdGxic4Xyeol3[Wx?	M4L1bFIxOTJ2NEW5
HBL-2	MUjDfZRwfG:6aXOgRZN{[Xl?	MnjCOUDPxE1i	MnvrPVYhcA>?	NG\sToFFVVOR	NYHIZYJrW2yrZ3j0cJkhcW6qaXLpeJMh[2WubDDzeZJ3cX[jbB?=	M17TSVIxOTJ2NEW5
JVM-2	NH7ZdIJEgXSxdH;4bYMhSXO\|YYm=	MlPaOUDPxE1i	NVPhb3ZKQTZiaB?=	NXvXPIMxTE2VTx?=	MlLjV4xq\2i2bImgbY5pcWKrdIOgZ4VtdCC\|dYL2bZZidA>?	M3fxRVIxOTJ2NEW5
Z138	MW\DfZRwfG:6aXOgRZN{[Xl?	NXrEOmtxPSEQvF2g	MkPGPVYhcA>?	M1fBWWROW09?	Mo\zV4xq\2i2bImgbY5pcWKrdIOgZ4VtdCC\|dYL2bZZidA>?	M4n3cFIxOTJ2NEW5
RWPE	MW\JcpZie2m4ZTDBd5NigQ>?	M4DYWlI2KM7:TR?=	M1L1PFQ5KGh?	MkXGSG1UVw>?	MmTBV4lodmmoaXPhcpRtgSC{ZXT1Z4V{KEWURz3kdol3\W5iY3XscEBqdn[jc3nvci=>	M1PUZlIyPTd3OE[1
VCaP	NXzHd2ZHUW64YYPpeoUhSXO\|YYm=	NVe2cnd{OjVizszN	NYfHTHl{PDhiaB?=	MkfpSG1UVw>?	Moe1V4lodmmoaXPhcpRtgSC{ZXT1Z4V{KEWURz3kdol3\W5iY3XscEBqdn[jc3nvci=>	NUnw[VFWOjF3N{W4OlU>
Mouse H2AX−/− ES Cells	Mon0R5l1d3SxeHnjJGF{e2G7	M37Wb\|IvPSEQvF2=	NFiyUY0zOCCq		NEjnfWxUcWewaX\pZ4FvfGy7IHnubIljcXS\|IHPlcIwhe3W{dnn2ZYw>	NYXJSXEzOjN\|NUW0PFk>
Mouse ATM−/− ES Cells	NIOyVWFEgXSxdH;4bYMhSXO\|YYm=	MoniNk42KM7:TR?=	M2jPclIxKGh?		NGG1TnRUcWewaX\pZ4FvfGy7IHnubIljcXS\|IHPlcIwhe3W{dnn2ZYw>	MYWyN\|M2PTR6OR?=
H1650	M1XCSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWGyNEDPxE1?	MVuxOFQhcA>?		MUjJR\|UxRTF3LkS3JO69VQ>?	MWmyN\|I{QThyOR?=
H1650PTEN+	NWrlNZRHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFeyOIEzOCEQvF2=	NFHIeGYyPDRiaB?=		NUnSZpV{UUN3ME21NE45OyEQvF2=	MkexNlMzOzl6MEm=
PC-9	NID4T4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHzJe3MzOCEQvF2=	MmXlNVQ1KGh?		M331R2lEPTB;NT64PEDPxE1?	Ml;HNlMzOzl6MEm=
PC-9PTEN−	NH7W[ZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH\QNJUzOCEQvF2=	NUfJWGFXOTR2IHi=		MUDJR\|UxRTZwNUKg{txO	MoXQNlMzOzl6MEm=
MDA-MB-231	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MYO1JIRigQ>?		MnjLTWM2OD14Lkmg{txO	MWOyN\|c3ODR7Nh?=
MDA-MB-468	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NV76OGF3PSCmYYm=		MWXJR\|UxRTVwMDFOwG0>	M{TrTVI{PzZyNEm2
BT20	MkflS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		Ml3VOUBl[Xl?		NEHtW5VKSzVyPUeuO{DPxE1?	Ml7INlM4PjB2OU[=
HCC1143	NI\ZNnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NVvmT3RRPSCmYYm=		NHvi[opKSzVyPUGxMlEh\|ryP	NUPOcVVbOjN5NkC0PVY>
HCC1937	MoP0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NVnSO5J6PSCmYYm=		NIrUb\|VKSzVyPUGyMlYh\|ryP	NHnmRVYzOzd4MES5Oi=>
Hs578t	Mm\3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NIDMUGE2KGSjeR?=		MUDJR\|UxRTVwNjFOwG0>	MnnCNlM4PjB2OU[=
Hs578t(si)	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MW[1JIRigQ>?		M2fkOWlEPTB;Nz61JO69VQ>?	Ml\5NlM4PjB2OU[=
BT474	NYjMR5lPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MWK1JIRigQ>?		NH3zPIxKSzVyPUG5Mlgh\|ryP	NFjQ[mwzOzd4MES5Oi=>
JIMT1	MorrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M4DIU\|Uh\GG7		MYfJR\|UxRTdwNzFOwG0>	NI\3W3UzOzd4MES5Oi=>
SKBR3	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MV:1JIRigQ>?		MnfvTWM2OD1zMT6xJO69VQ>?	NYjoWlM1OjN5NkC0PVY>
SUM159	NVTTXZg5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NIi0SI42KGSjeR?=		NYXDeVdNUUN3ME20MlIh\|ryP	M3;vOlI{PzZyNEm2
CAMA1	NVGy[2VDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NVOxb5pTPSCmYYm=		M2fITWlEPTB;MUWuPEDPxE1?	M1riOVI{PzZyNEm2
MCF7	NFPNZ5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M1;mV\|Uh\GG7		MoK5TWM2OD13Lkig{txO	M3jNXFI{PzZyNEm2
T47D	NY[3[5h1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MmLmOUBl[Xl?		NULKXIptUUN3ME25MlYh\|ryP	Mn7MNlM4PjB2OU[=
HCT116	NXrsO4toT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYCxXVVyOTByIN88US=>	MnTEOFghcA>?	M4XaVWROW09?	MV3JR\|UxRTJwNTFOwG0h	M1nWRVI1PTd5OUSx
SW1116	NV\zbmZNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHjHeoIyODBizszN	NGnncJY1QCCq	MkPBSG1UVw>?	NUPoU5g6UUN3ME2xNFAh\|ryP	MXqyOFU4Pzl2MR?=
HT29	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWC1XHJnOTByIN88US=>	NVjlfGlkPDhiaB?=	NWrH[\|VpTE2VTx?=	MVXJR\|UxRTF2Lkeg{txO	M{PTRlI1PTd5OUSx
LoVo	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkTvNVAxKM7:TR?=	M1u2[FQ5KGh?	MVrEUXNQ	M{XheWlEPTB;MUOuOEDPxE1?	NXW2WXd6OjR3N{e5OFE>
HCT-15	Mn3rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3vPV\|ExOCEQvF2=	M3KydVQ5KGh?	MlfESG1UVw>?	NEjifnJKSzVyPUGwJO69VQ>?	NYPBemN7OjR3N{e5OFE>
SW48	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXr2SI9EOTByIN88US=>	NXzySo9wPDhiaB?=	MlnuSG1UVw>?	NW[3S2M{UUN3ME25MlUh\|ryP	MlmwNlQ2Pzd7NEG=
C-1	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVSxNFAh\|ryP	NXzFW4R4PDhiaB?=	MYDEUXNQ	MX3JR\|UxRTdwNjFOwG0>	NYX0NpRjOjR3N{e5OFE>
RKO	NYGzcVB[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVjnUXZXOTByIN88US=>	M4TQWFQ5KGh?	M1\KPGROW09?	NFuwZ\|NKSzVyPUWuPUDPxE1?	NXLGb5RKOjR3N{e5OFE>
HCT116	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVzse41EOTByIN88US=>	NUPZV5BuPDhiaB?=	M3z0[GROW09?	MoPYVI91\W62aXH0[ZMhW05vM{igZ5l1d3SxeHnjbZR6KA>?	NHLjO5gzPDV5N{m0NS=>
SW1116	NI\CfWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1GyblExOCEQvF2=	NYXmNpZKPDhiaB?=	M3fkdGROW09?	Mnq2VI91\W62aXH0[ZMhW05vM{igZ5l1d3SxeHnjbZR6KA>?	MljKNlQ2Pzd7NEG=
HT29	NX;peodbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWXtNJRoOTByIN88US=>	NEW2eHk1QCCq	MnLiSG1UVw>?	NXfDOVcxWG:2ZX70bYF1\XNiU16tN\|gh[3m2b4TvfIlkcXS7IB?=	NFuwW5YzPDV5N{m0NS=>
LoVo	M{jOZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGLSNVMyODBizszN	MkG4OFghcA>?	NF[3SIpFVVOR	M1rtcHBwfGWwdHnheIV{KFOQLUO4JIN6fG:2b4jpZ4l1gSB?	NIjzOIQzPDV5N{m0NS=>
SW48	M1nDU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlfZNVAxKM7:TR?=	Mln4OFghcA>?	M3vqd2ROW09?	NYjrdopFWG:2ZX70bYF1\XNiU16tN\|gh[3m2b4TvfIlkcXS7IB?=	NEjFRXAzPDV5N{m0NS=>
C-1	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWPDcVJXOTByIN88US=>	M2HOc\|Q5KGh?	MmDPSG1UVw>?	M2nxSHBwfGWwdHnheIV{KFOQLUO4JIN6fG:2b4jpZ4l1gSB?	MViyOFU4Pzl2MR?=
RKO	NF3wNFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIXWUlcyODBizszN	NGPXNFY1QCCq	NFqye4pFVVOR	M2D2cnBwfGWwdHnheIV{KFOQLUO4JIN6fG:2b4jpZ4l1gSB?	M4jmfFI1PTd5OUSx
HCT116	MoPHSpVv[3Srb36gRZN{[Xl?	MmXkNVAhdk1?	Mle3NVIhcA>?	NHn2VI9FVVOR	MV7JcoNz\WG\|ZYOgSG5CKGSxdXLs[U1{fHKjbnSgZpJm[Wu\|IHnu[JVk\WRiYomgV24uOzh?	Mmm5NlQ2Pzd7NEG=
HT29	NYf0N2NoTnWwY4Tpc44hSXO\|YYm=	NGnSWG8yOCCwTR?=	MnLjNVIhcA>?	NVv4NJdJTE2VTx?=	M4rH[Wlv[3KnYYPld{BFVkFiZH;1ZoxmNXO2cnHu[EBjemWja4OgbY5lfWOnZDDifUBUVi1\|OB?=	MU[yOFU4Pzl2MR?=
TE-6	MUXGeY5kfGmxbjDBd5NigQ>?	NH;wdpY2KM7:TTC=	NGPPNm0yOiCq	NGrXVlZFVVOR	NVLWXJhLUW6mdXPld{BIOi:PIHHydoV{fA>?	M{fLelI1OjF7MU[0
TE-6	NHfGUJpHfW6ldHnvckBCe3OjeR?=	M{nme\|Uh\|ryPIB?=	NGGxOY4zPCCq	MnH6SG1UVw>?	M1;Lcmlv[3KnYYPld{BqdiCmb4XicIUhe3S{YX7kJIJz\WGtczCoSHNDeyl?	MYKyOFIyQTF4NB?=
Hep3B	M4G3eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2f0RVQxKM7:TTC=	NXThe\|doPzJiaB?=	NVrtdIs2TE2VTx?=	M4DX[3N6dmW{Z3nzeIlk[WyueTDpcohq[mm2czDj[YxtKGe{b4f0bEB4cXSqIFTIUWVS	MV2yOVA4Ojd3Mh?=
Huh7	M4C2T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXS0NEDPxE1i	NH3HO4I4OiCq	MWXEUXNQ	MUPTfY5memerc4TpZ4FtdHliaX7obYJqfHNiY3XscEBoem:5dHige4l1cCCGSF3FVS=>	MmK3NlUxPzJ5NUK=
Hep3B	NIXhTlNHfW6ldHnvckBCe3OjeR?=	MV20NEDPxE1i	NFzEPG4zPCCq	MlzTSG1UVw>?	NV:xeVM3UW6mdXPld{BTV1NicILv[JVkfGmxbjD3bZRpKESKTVXR	MViyOVA4Ojd3Mh?=
Huh7	NVHKVpNjTnWwY4Tpc44hSXO\|YYm=	M1KwWVQxKM7:TTC=	M1qyO\|I1KGh?	MUfEUXNQ	NWjISm9DUW6mdXPld{BTV1NicILv[JVkfGmxbjD3bZRpKESKTVXR	NW\h[G1TOjVyN{K3OVI>
Hep3B	M1\wWGZ2dmO2aX;uJGF{e2G7	MXW0NEDPxE1i	MnLENlQhcA>?	NIXVcG1FVVOR	MXXJcoR2[2W\|IHPlcIwh[XW2b4DoZYd6KHerdHigSGhOTVF?	M{LLZlI2ODd{N{Wy
Huh7	NVLs[I5CTnWwY4Tpc44hSXO\|YYm=	MYG0NEDPxE1i	Mlz4NlQhcA>?	NVW4fll4TE2VTx?=	NYPXdIlsUW6mdXPld{Bk\WyuIHH1eI9xcGGpeTD3bZRpKESKTVXR	NWm1cYZ[OjVyN{K3OVI>
SGC-7901	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVHWSo9[OzEEoN88US=>	NUTiTXlHPDhiaB?=	M375W2ROW09?	NVzLWnJiSmyxY3ugc5hidGmybHH0bY4ucW6mdXPl[EBk\WyuIHTlZZRp	MYmyOVc3PzB5Nh?=
COLO-800	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnjBTWM2OD1yLkS0NVY1KM7:TR?=	MofyV2FPT0WU
EoL-1-	NEmyWHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlrmTWM2OD1yLkW2OFQ3KM7:TR?=	M3W5e3NCVkeHUh?=
NCI-H209	NHn5PXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIHROGRKSzVyPUCuPVE2PTZizszN	M3\0cHNCVkeHUh?=
ES1	MkDXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Ml7hTWM2OD1zLkGxOFA5KM7:TR?=	NEPWPVJUSU6JRWK=
NKM-1	NGf1V2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXjKR4ZRUUN3ME2xMlI2OzR5IN88US=>	NUfZXnZ4W0GQR1XS
NTERA-S-cl-D1	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYPJR\|UxRTFwM{OzOFEh\|ryP	MWDTRW5ITVJ?
MHH-ES-1	M4Xrb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWjJR\|UxRTFwNkKwOlch\|ryP	MoXTV2FPT0WU
ES8	NEjDRVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUP3UIRXUUN3ME2xMlczPDF2IN88US=>	NYjM[mRDW0GQR1XS
NCI-H720	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUHJR\|UxRTJwMkC2PVkh\|ryP	NG\KW2tUSU6JRWK=
EW-3	M4TIXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUjJR\|UxRTJwMke1N\|Qh\|ryP	MXXTRW5ITVJ?
D-566MG	M3vxT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVfJR\|UxRTJwNES1Olgh\|ryP	NULteHN{W0GQR1XS
697	NFT0SpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYrpboM2UUN3ME2yMlg1OTd\|IN88US=>	MlrQV2FPT0WU
ES5	NHfQN3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWT2WWg{UUN3ME2yMlg5OTh7IN88US=>	Mn32V2FPT0WU
COLO-684	M2CyZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXHJR\|UxRTNwNUG2PVYh\|ryP	MWTTRW5ITVJ?
ML-2	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEP1coZKSzVyPUOuOlAxPThizszN	NUPueGQ5W0GQR1XS
MC-IXC	M3y2dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MknjTWM2OD1\|Lk[zN\|k{KM7:TR?=	NGXXbnJUSU6JRWK=
DB	Mln0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWToS4diUUN3ME2zMlY2PDR6IN88US=>	M{CyN3NCVkeHUh?=
HCC2218	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmDyTWM2OD1\|LkezNVA{KM7:TR?=	NVO5[IVMW0GQR1XS
NCI-H510A	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4GwbmlEPTB;Mz64NlczPCEQvF2=	M2LvNXNCVkeHUh?=
NCI-H526	NV[2S2tkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVHXUlcyUUN3ME2zMlg3QTV6IN88US=>	NEG5RnJUSU6JRWK=
MV-4-11	NFfXTHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUjrV4dZUUN3ME20MlE{OzN2IN88US=>	NWKyZ\|QyW0GQR1XS
PA-1	M3jMWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NV\6XXdyUUN3ME20MlI2OjlizszN	NV[4[odJW0GQR1XS
EW-22	M4\jXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUG4cYp5UUN3ME20MlM2QDZizszN	MnXpV2FPT0WU
KASUMI-1	NVnQWGhpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVrtdndvUUN3ME20MlQxOTB7IN88US=>	MnXCV2FPT0WU
LU-139	NFTtRW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M13QZWlEPTB;ND63OVgzQSEQvF2=	MUfTRW5ITVJ?
SBC-1	NV62WphWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NELKfGlKSzVyPUSuPFA6ODhizszN	MkDYV2FPT0WU
H4	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHzCOVhKSzVyPUSuPFk1PDNizszN	NXPvelU5W0GQR1XS
EW-11	Ml\GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXXHXVFXUUN3ME21MlA5ODd{IN88US=>	NXrOTlJZW0GQR1XS
NBsusSR	NXvONIJwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MY\JR\|UxRTVwMUKwOVUh\|ryP	NYHwXlA{W0GQR1XS
RPMI-8226	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1riXGlEPTB;NT6xOVI1PCEQvF2=	MmDNV2FPT0WU
DEL	NUm4UFBUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUnWR4dGUUN3ME21MlIxODB4IN88US=>	NWPmV\|NrW0GQR1XS
ES4	NFjHcpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHi2VYdKSzVyPUWuOVE{QDlizszN	NHPlT4JUSU6JRWK=
GCT	MnfUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{DFeGlEPTB;NT61Olg2PiEQvF2=	MoLJV2FPT0WU
NCI-H1048	Mn[2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NH[zTpJKSzVyPUWuPVczPzNizszN	M2O0O3NCVkeHUh?=
NCI-SNU-1	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmnmTWM2OD14LkCyNkDPxE1?	NHLZOnhUSU6JRWK=
ES7	MofOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVzJR\|UxRTZwMEO1O\|ch\|ryP	NG\KXVJUSU6JRWK=
SW982	M3PRd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFvQbopKSzVyPU[uNFkyOzdizszN	NXjNbod6W0GQR1XS
L-363	M3\4fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NV[ybGZpUUN3ME22MlM{QTd2IN88US=>	NELFUHZUSU6JRWK=
HT-1080	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mn;HTWM2OD14LkS5Olg{KM7:TR?=	NYnpSpRuW0GQR1XS
HAL-01	M3TEZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVnJR\|UxRTZwNUGwPUDPxE1?	M2\VdnNCVkeHUh?=
NB14	Mlf5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3e4OWlEPTB;Nj62OFA{QSEQvF2=	M3zneHNCVkeHUh?=
EW-13	M2r1N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUjV[ZlvUUN3ME22Mlc4PDJ2IN88US=>	NYT4OWRMW0GQR1XS
NY	M4\sUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlznTWM2OD14Lkm0OlA2KM7:TR?=	NXi1TWFiW0GQR1XS
NCI-SNU-5	M4TEW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWCxRZF3UUN3ME23MlExPDN\|IN88US=>	NIrBcYNUSU6JRWK=
MS-1	MlfwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFrmcFdKSzVyPUeuNVc1QTRizszN	MnHqV2FPT0WU
EW-16	NGDNUodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkW3TWM2OD15LkOxPFYyKM7:TR?=	M2DMcHNCVkeHUh?=
LU-65	M2r6TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MV\JR\|UxRTdwNEi0NVch\|ryP	M2LqTnNCVkeHUh?=
HGC-27	NI\lV4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXLJR\|UxRTdwN{KxO\|Mh\|ryP	NFPqSWVUSU6JRWK=
CTB-1	NUC5epd[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NH;pcZBKSzVyPUeuO\|YyPzVizszN	Mmm1V2FPT0WU
5637	NIHOboVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUn6fIRSUUN3ME23MlkzQDZizszN	MVHTRW5ITVJ?
U251	MnzxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4PkTWlEPTB;Nz65OFAyPiEQvF2=	NXu5cVhjW0GQR1XS
HOS	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MX\JR\|UxRThwMkOwNFch\|ryP	NF\sS2tUSU6JRWK=
DOHH-2	NUfaeolJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVXJR\|UxRThwMkO1PEDPxE1?	MXzTRW5ITVJ?
EW-1	NYXDXJY{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4TGdmlEPTB;OD6zNFA5QCEQvF2=	MVHTRW5ITVJ?
BV-173	NHi4WVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mo\FTWM2OD16LkW1OVQh\|ryP	NGHYdmFUSU6JRWK=
8-MG-BA	NHHnT2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXrJR\|UxRThwNki5PFgh\|ryP	M4fMd3NCVkeHUh?=
NB69	NWGxellOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHjMbpNKSzVyPUiuO\|A6OjFizszN	M{CzTnNCVkeHUh?=
NCI-H69	NEnLNWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXjJR\|UxRTlwOUC5OlEh\|ryP	MoDOV2FPT0WU
RS4-11	M1HydGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2jMe2lEPTB;MUGuNlIxQCEQvF2=	NGi2R2JUSU6JRWK=
ONS-76	NEj4dIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEHPSGFKSzVyPUGxMlI6PDdizszN	NXnufZZzW0GQR1XS
SF539	MoPYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUHjXXV[UUN3ME2xNU41QDh7IN88US=>	NX3Nc25VW0GQR1XS
HuO-3N1	NUnQSGd[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUnJR\|UxRTFzLkW3PVYh\|ryP	M4DsRnNCVkeHUh?=
NCI-H1651	NF3UNYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHn1UWNKSzVyPUGyMlMyOTVizszN	NGLWTpJUSU6JRWK=
KARPAS-45	M2DMdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXPJR\|UxRTF{LkO3OkDPxE1?	Ml6xV2FPT0WU
SK-NEP-1	M3Pp[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEDVbYpKSzVyPUGyMlQ3ODlizszN	NYHOenIyW0GQR1XS
LAMA-84	MlzXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWTJR\|UxRTF\|LkGwPVUh\|ryP	MoW5V2FPT0WU
NCI-H1155	M4\X[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2rIXGlEPTB;MUOuNlg2PiEQvF2=	M3i5O3NCVkeHUh?=
CTV-1	NI\0SWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4ewUmlEPTB;MUOuOFQ2KM7:TR?=	MXrTRW5ITVJ?
QIMR-WIL	Mn7rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Ml;sTWM2OD1zMz63PFE1KM7:TR?=	M3[0cnNCVkeHUh?=
H9	NWXiPFJVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGnzT5RKSzVyPUGzMlg1PzVizszN	NFmwWG5USU6JRWK=
SK-MEL-1	NXHKU3c3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mm[3TWM2OD1zMz65N\|Q4KM7:TR?=	M{HwT3NCVkeHUh?=
HD-MY-Z	NVnsRodnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVzxcXgxUUN3ME2xOE4xPjN5IN88US=>	Mk[5V2FPT0WU
TI-73	MmXoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYjJR\|UxRTF2LkKzOVYh\|ryP	NVrZWHBpW0GQR1XS
JVM-3	NWHj[ohnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MorVTWM2OD1zNT61O\|E3KM7:TR?=	M{[wVHNCVkeHUh?=
D-247MG	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUHBUWlpUUN3ME2xOU42QTNizszN	MWfTRW5ITVJ?
VA-ES-BJ	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmXHTWM2OD1zNT62NFk4KM7:TR?=	M4TTPHNCVkeHUh?=
NOS-1	Mn7XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoPhTWM2OD1zNT62OVIzKM7:TR?=	NYq5Vlk4W0GQR1XS
MOLT-4	MkjlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MX3JR\|UxRTF4Lke1NkDPxE1?	MWPTRW5ITVJ?
Mo-T	NHS5dXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1jmdGlEPTB;MUeuNFg1QSEQvF2=	NFv3TW1USU6JRWK=
NCI-H1770	NVv0Tlg5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXexOnBEUUN3ME2xO{4yPTR\|IN88US=>	MVjTRW5ITVJ?
COLO-320-HSR	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2K1[mlEPTB;MUeuNVgzPyEQvF2=	M4L2V3NCVkeHUh?=
TE-12	M4r1bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXrP[2JHUUN3ME2xO{44ODV2IN88US=>	M3O1Z3NCVkeHUh?=
NCI-H82	MmLMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVHJR\|UxRTF5Lki3Nlgh\|ryP	NH64OVdUSU6JRWK=
NEC8	Ml;lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NX2zOWZkUUN3ME2xPE4yOzF4IN88US=>	MYnTRW5ITVJ?
HSC-3	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NF\hblRKSzVyPUG4Mlc1OTRizszN	MlrYV2FPT0WU
NCI-H1092	MnzFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MojUTWM2OD1zOD63OVk2KM7:TR?=	NUGwPIVOW0GQR1XS
NCI-H292	NF7kTFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NX\VUVFwUUN3ME2xPU4xPDh7IN88US=>	MnXDV2FPT0WU
L-428	M4nKfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVPDWFBkUUN3ME2xPU42PTlizszN	NUTFNIFFW0GQR1XS
LU-134-A	NV;QNIhET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlPFTWM2OD1zOT61O\|Ih\|ryP	M2HG[3NCVkeHUh?=
GI-ME-N	NIj4SlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHfxO2VKSzVyPUG5MlU4PDdizszN	Ml[wV2FPT0WU
ALL-PO	M1v4V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGGxcopKSzVyPUG5MlU6PzJizszN	NWTDVYx4W0GQR1XS
D-283MED	MlnZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1m2Z2lEPTB;MUmuPVE2KM7:TR?=	MmjzV2FPT0WU
D-423MG	NILtUXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVTJR\|UxRTF7Lkm5Olch\|ryP	NV;kSpF4W0GQR1XS
CAKI-1	M1nJfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVv3[YQyUUN3ME2yNE4zOjF7IN88US=>	NFPvT49USU6JRWK=
ETK-1	NFryXlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mne2TWM2OD1{MD6yOlE2KM7:TR?=	Mn2zV2FPT0WU
G-402	MoXqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYfJR\|UxRTJyLkWzN\|Qh\|ryP	NEDkfZJUSU6JRWK=
HL-60	M{C5Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoX3TWM2OD1{MT6xOlE{KM7:TR?=	NXnvZVB7W0GQR1XS
A2058	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHT5TVVKSzVyPUKxMlQ1PzdizszN	NUiyeI5[W0GQR1XS
CHP-212	NXLQO\|RyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVjXcph7UUN3ME2yNU46ODVzIN88US=>	MkDRV2FPT0WU
KY821	M2m2XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MV;JR\|UxRTJzLkm3OUDPxE1?	MWHTRW5ITVJ?
TYK-nu	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmfRTWM2OD1{Mj6wOlUyKM7:TR?=	NVzRe2NrW0GQR1XS
JVM-2	MoLPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWLq[4U1UUN3ME2yNk4zQTh\|IN88US=>	MnmwV2FPT0WU
KU812	NV;aToI4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXXJR\|UxRTJ{LkezNVIh\|ryP	M3TnNXNCVkeHUh?=
MKN28	NWrjTGFCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mn\VTWM2OD1{Mj65NFE2KM7:TR?=	MYDTRW5ITVJ?
ECC10	M{KzVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnnZTWM2OD1{Mz63OFEh\|ryP	NGLkVGtUSU6JRWK=
BHT-101	NILHVVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYq0XlZGUUN3ME2yOE4xODB6IN88US=>	MlnZV2FPT0WU
DU-4475	M1\Vbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4X2TWlEPTB;MkSuN\|M{PyEQvF2=	NFHDR5hUSU6JRWK=
769-P	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFfmV\|hKSzVyPUK0Mlg1PjZizszN	NUDaXoJTW0GQR1XS
HEC-1	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnrPTWM2OD1{NT60OFUh\|ryP	Mo\oV2FPT0WU
MOLT-13	M1j5dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmqyTWM2OD1{NT61N\|MyKM7:TR?=	MlX4V2FPT0WU
8505C	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3;WWWlEPTB;Mk[uOFk4PyEQvF2=	NXXrV24xW0GQR1XS
GB-1	M1mzZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2i0cGlEPTB;Mk[uO\|E4PiEQvF2=	M13vcnNCVkeHUh?=
SF126	NVvKWZd1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXzJR\|UxRTJ4Lke2OFgh\|ryP	NUXIOXc{W0GQR1XS
A4-Fuk	Ml7qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mn;iTWM2OD1{Nz6xNlcyKM7:TR?=	NFPlfpFUSU6JRWK=
OVCAR-8	NIfrVGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mk\BTWM2OD1{Nz6xOVM6KM7:TR?=	M2\O[3NCVkeHUh?=
NCI-H1304	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVfxVYZDUUN3ME2yO{42PCEQvF2=	NVvObJBIW0GQR1XS
GR-ST	NYiwOGVYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlTyTWM2OD1{OD6wOFch\|ryP	M4XmdHNCVkeHUh?=
G-401	NFjF[JRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmLBTWM2OD1{OD61NFk3KM7:TR?=	MV7TRW5ITVJ?
LXF-289	M{PaS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVzJR\|UxRTJ6LkW2OVEh\|ryP	M1z6c3NCVkeHUh?=
DBTRG-05MG	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWDJR\|UxRTJ6LkmyNFQh\|ryP	M1\2RnNCVkeHUh?=
YKG-1	NUDLW\|FUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MULJR\|UxRTJ7Lki2PEDPxE1?	MV\TRW5ITVJ?
GAMG	NVvsNmh5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUjJR\|UxRTJ7Lkm5N{DPxE1?	M2rrXnNCVkeHUh?=
HCT-116	Moe0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkfxTWM2OD1\|MD6wOVQ5KM7:TR?=	MYfTRW5ITVJ?
S-117	Mn:2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1f5emlEPTB;M{GuNlI2PyEQvF2=	M3XtSHNCVkeHUh?=
NCI-H1693	MkDjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnuyTWM2OD1\|Mz62OVQzKM7:TR?=	M2XIWXNCVkeHUh?=
A427	NXe3dnZiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NE\pRmhKSzVyPUOzMlk6PzZizszN	NYrRRY5jW0GQR1XS
HT-29	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVnJR\|UxRTN2Lk[wN\|Ih\|ryP	NWK3SHFJW0GQR1XS
P12-ICHIKAWA	Moj4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEXWdZlKSzVyPUO0Mlc1QTFizszN	M4jXSHNCVkeHUh?=
CAL-51	NXLW[21PT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIPsR\|JKSzVyPUO1MlA4ODlizszN	MWTTRW5ITVJ?
Ramos-2G6-4C10	M3K2UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVfhVFR1UUN3ME2zOU4zPDJ3IN88US=>	MUfTRW5ITVJ?
SCH	MkPOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYHJR\|UxRTN4LkSxO\|Qh\|ryP	MlTwV2FPT0WU
SK-MEL-24	M2Hmdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUPwWVBkUUN3ME2zOk46ODR2IN88US=>	NGjiVGFUSU6JRWK=
SW1573	M125Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXW5Tno{UUN3ME2zPE44OjF4IN88US=>	M4TGV3NCVkeHUh?=
BALL-1	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV7qSmNIUUN3ME2zPU4zOTJ7IN88US=>	MlTaV2FPT0WU
BE-13	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXvlbpZsUUN3ME2zPU4{OjlizszN	NECxV5pUSU6JRWK=
GI-1	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NX62UGt7UUN3ME2zPU45PjR5IN88US=>	NF:2enpUSU6JRWK=
GOTO	NY\OTm5oT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYTJR\|UxRTN7LkmxN\|kh\|ryP	NYL2XIREW0GQR1XS
A673	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mlu1TWM2OD12MT6wN\|Q{KM7:TR?=	MoKzV2FPT0WU
KG-1	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIXDXHhKSzVyPUSzMlM6PCEQvF2=	M3zvWHNCVkeHUh?=
GP5d	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MULJR\|UxRTR2LkC2OlYh\|ryP	NGruOmZUSU6JRWK=
MFM-223	MofMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2jNeWlEPTB;NESuNVIzQCEQvF2=	MnHCV2FPT0WU
OAW-42	NWnENZFwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlTUTWM2OD12ND6yOlQ{KM7:TR?=	M2jr[3NCVkeHUh?=
C8166	M17ONGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NID2UZlKSzVyPUS1MlA5OjJizszN	NXHqNmx6W0GQR1XS
LU-99A	NFrEUXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3;XPWlEPTB;NE[uNVMzOiEQvF2=	M{TBXXNCVkeHUh?=
NCI-H23	M2DJOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4DaVWlEPTB;NE[uNVc5PSEQvF2=	MkPJV2FPT0WU
HO-1-N-1	M37ubGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIXDSWNKSzVyPUS3MlA6QThizszN	M4rqTnNCVkeHUh?=
A3-KAW	NHe2WmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2rhR2lEPTB;NEeuNVAxPyEQvF2=	MWTTRW5ITVJ?
CGTH-W-1	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NE\4fItKSzVyPUS3MlUxPjlizszN	MmD2V2FPT0WU
DJM-1	MmXSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Ml3XTWM2OD12Nz61OFE{KM7:TR?=	NU[ydnZ{W0GQR1XS
A101D	MkT5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYTJR\|UxRTR5Lk[zOVch\|ryP	MULTRW5ITVJ?
BB30-HNC	NGfTcVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NETkO2FKSzVyPUS4MlMxPzJizszN	MkD6V2FPT0WU
T98G	NGXQTGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NE\TRpJKSzVyPUS4MlQ3OzNizszN	NXnBWYZJW0GQR1XS
NCI-H1573	MknES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmfKTWM2OD12OT60OFYzKM7:TR?=	NUW3VXVIW0GQR1XS
MEG-01	NWjtU4FUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVzhWnFlUUN3ME20PU44PDFzIN88US=>	NVzwWll4W0GQR1XS
WM-115	M1nyWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mnq3TWM2OD12OT65NlIzKM7:TR?=	MVXTRW5ITVJ?

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western Blot	DR5/CHOP; PubMed: 25531448 PLoS One (A) U87 GBM cells were treated with Olaparib (10 µM) for the indicated time points, subjected to immunoblotting and analyzed for the expression of DR5. B-D) U87 (B), U373 (C) and LN229 GBM cells (D) were treated with increasing concentrations of Olaparib (µM) for 7 hours, subjected to immunoblotting and analyzed for the expression of CHOP and DR5. E–F) MDA-MB-468 (E) and MDA-MB-436 (F) were treated with increasing concentrations (µM) of Olaparib for 7 hours, harvested for immunoblotting and analyzed for the expression of DR5. γH2AX/H2AX; PubMed: 22933245 EMBO Mol Med FK866 exacerbates levels of γH2AX caused by olaparib. CAL51 cells were exposed to FK866 and/or olaparib for 48 h and cell lysates generated and immunoblotted for total and γH2AX. pATM; PubMed: 27686740 Cell cycle (C) Western blot analysis in HN9-cisR cells according to changes in olaparib doses. Olaparib induced pATM and 53BP1 activation in a dose-dependent manner in HN9-cisR cells. 53BP1; PubMed: 27686740 Cell cycle (C) Western blot analysis in HN9-cisR cells according to changes in olaparib doses. Olaparib induced pATM and 53BP1 activation in a dose-dependent manner in HN9-cisR cells. NF-kB; PubMed: 27686740 Cell cycle (C) Western blot analysis in HN9-cisR cells according to changes in olaparib doses. Olaparib induced pATM and 53BP1 activation in a dose-dependent manner in HN9-cisR cells. pS6/S6; PubMed: 24831086 Oncotarget HCC1937 cells (BRCA1-inactive) were treated with 10 nM olaparib with indicated times. Whole-cell lysates were prepared and analyzed by Western blotting with the indicated antibodies.	25531448 22933245 27686740 24831086
Immunofluorescence	DNA damage; PubMed: 27686740 Cell Cycle (A) A comet assay and (B) γH2AX immunofluorescence assay were performed 72 h after olaparib treatment to identify DNA damage. A relatively higher level of DNA damage was observed in HN9-cisR cells; however, olaparib also induced slight DNA damage in olaparib-resistant HN4-cisR cells. Magnification: × 100 (comet assay); × 400 (γH2AX). γH2AX; PubMed: 28069876 Mol Cancer Ther Representative images of immunofluorescence (IF) staining for γH2AX in 22RV1 cells treated with of BI2536 (5 nM), Olaparib (10 µM) or both for 24 h. 22RV1 cells (1 × 105) were plated in 6-well plates on day 0 and then treated with BI2536, Olaparib or both for 24 h.	27686740 28069876
Growth inhibition assay	Cell viability ; PubMed: 25531448 PLoS One A-D): U87 (A), U373 (B), LN229 (C) and MDA-MB-468 (D) cells were treated with suboptimal dosages of TRAIL (A: 100 ng/ml, B: 25 ng/ml, C: TRAIL 200 ng/ml, D: 10 ng/ml), Olaparib (A–C: 10 µM, D: 5 µM) or the combination of both reagents for 48 hours. Thereafter, MTT assays were performed to determine cellular viability.	25531448
ELISA	IL-8; PubMed: 28456021 Virology ELISA measuring PAR levels in Akata-EBV cells. Cells were treated with 2.5 μM olaparib for 24 h to inhibit PARP activity. Data are shown as pg of PAR per μg of protein. GLP-1; PubMed: 29392078 Aging Dis Olaparib enhances promotes GLP-1 secretion in NCI-H716 cells Cells were stimulated for 30 minutes with or without 16 mM glucose. GLP-1 was measured by ELISA. Bars represent the mean of three independent experiments normalized to the control. Error bars indicate standard deviation. Statistical analyses were performed by two-tailed Student’s t-test and significance is denoted by asterisks where *P<0.05.	28456021 29392078

In vivo

Combining with temozolomide, Olaparib (10 mg/kg, p.o.) significantly suppresses tumor growth in SW620 xenografts. ^[1] Olaparib shows great response to Brca1^-/-;p53^-/- mammary tumors (50 mg/kg i.p. per day), while no responses to HR-deficient Ecad^-/-;p53^-/- mammary tumors. Olaparib even does not show dose-limiting toxicity in tumor-bearing mice. ^[3] Olaparib has been used to treat with BRCA mutated tumors, such as ovarian, breast and prostate cancers. Moreover, Olaparib shows selectively inhibition to ATM (Ataxia Telangiectasia Mutated)-deficient tumor cells, which indicates to be a potential agent for treating ATM mutant lymphoid tumors. ^[4]

Protocol

Kinase Assay: ^[1]	- Collapse FlashPlate assay (96-well screening assay): To columns 1 through 10, 1 μL of Olaparib (in DMSO) is added, and 1 μL DMSO only is added to the positive (POS) and negative (NEG) control wells (columns 11 and 12, respectively) of a pretreated FlashPlate. PARP-1 is diluted 1:40 in buffer (buffer B: 10% glycerol (v/v), 25 mM HEPES, 12.5 mM MgCl₂,50 mM KCl, 1 mM DTT, 0.01% NP-40 (v/v), pH 7.6) and 40 μL added to all 96 wells (final PARP-1 concentration in the assay is ~1 ng/μL). The plate is sealed and shaken at RT for 15 min. Following this, 10 μL of positive reaction mix (0.2 ng/μL of double-stranded oligonucleotide [M3/M4] DNA per well, 5 μM of NAD⁺ final assay concentration, and 0.075 μCi ³H-NAD⁺ per well) is added to the appropriate wells (columns 1-11). The negative reaction mix, lacking the DNA oligonucleotide, is added to column 12 (with the mean negative control value used as the background). The plate is resealed and shaken for a further 60 min at RT to allow the reaction to continue. Then, 50 μL of ice-cold acetic acid (30%) is added to each well to stop the reaction, and the plate is sealed and shaken for a further 60 min at RT. Tritiated signal bound to the FlashPlate is then determined in counts per minute (CPM) using the TopCount plate reader.
Cell Research: ^[1]	- Collapse Cell lines: Breast cancer cell lines including SW620 colon, A2780 ovarian, HCC1937, Hs578T, MDA-MB-231, MDA-MB-436, and T47D Concentrations: 1-300 nM Incubation Time: 7-14 days Method: The cytotoxicity of Olaparib is measured by clonogenic assay. Olaparib is dissolved in DMSO and diluted by culture media before use. The cells are seeded in six well plates and left to attach overnight. Then Olaparib is added at various concentrations and the cells are incubated for 7-14 days. After that the surviving colonies are counted for calculating the IC50. (Only for Reference)
Animal Research: ^[3]	- Collapse Animal Models: Brca1^-/-;p53^-/- mammary tumors are generated in K14cre;Brca1^F/F;p53^F/F mice. Formulation: 50 mg/mL stocks in DMSO with 10% 2-hydroxyl-propyl-β-cyclodextrine/PBS Dosages: 50 mg/kg Administration: Administered via i.p. injection at 10 μL/g of body weight (Only for Reference)

References

[4] Weston VJ, et al, Blood, 2010, 116(22), 4578-4587.

- Collapse

Solubility (25°C)

In vitro	DMSO	86 mg/mL warmed (197.94 mM)
	Water	0.002 mg/mL (0.0 mM)
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 4% DMSO+30% PEG 300+ddH2O For best results, use promptly after mixing.	5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Olaparib (AZD2281, Ku-0059436) SDF

Molecular Weight	434.46
Formula	C₂₄H₂₃FN₄O₃
CAS No.	763113-22-0
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	N/A

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04024254	Not yet recruiting	Drug: Folic Acid Tablet	Ovarian Cancer\|Breast Cancer\|Folic Acid Deficiency	Rush University Medical Center	August 2019	Phase 2\|Phase 3
NCT04005690	Recruiting	Drug: Cobimetinib\|Drug: Olaparib	Resectable Pancreatic Ductal Adenocarcinoma\|Stage 0 Pancreatic Cancer AJCC v8\|Stage I Pancreatic Cancer AJCC v8\|Stage IA Pancreatic Cancer AJCC v8\|Stage IB Pancreatic Cancer AJCC v8\|Stage II Pancreatic Cancer AJCC v8\|Stage IIA Pancreatic Cancer AJCC v8\|Stage IIB Pancreatic Cancer AJCC v8\|Stage III Pancreatic Cancer AJCC v8	OHSU Knight Cancer Institute\|National Cancer Institute (NCI)	August 1 2019	Phase 2
NCT03786796	Recruiting	Drug: Olaparib	Renal Cell Carcinoma\|Metastatic Renal Cell Carcinoma\|Kidney Cancer\|Renal Carcinoma\|Kidney Cancer Metastatic	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins\|AstraZeneca	June 3 2019	Phase 2
NCT03745950	Not yet recruiting	Drug: Olaparib Oral Capsule\|Drug: Placebo oral capsule	Endometrial Carcinoma	ARCAGY/ GINECO GROUP	February 1 2019	Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
How to prepare the solution of the compound (S1060) for in vivo study?
Answer:
We recommend the following formulation: 4% DMSO+30% PEG300+ 66%H2O. It is a clear solution and can be used for IP injection.
Question 2:
I saw that the solubility of the compound for in vivo on the website had been changed, why the change has been made?
Answer:
For the formulation for in vivo, the compound dissolving in 15% Captisol (former solubility) is a suspension, and it is fine for oral gavage. And now, dissolving in 4% DMSO+30% PEG 300+ddH2O is a clear solution, and is for injection.
Question 3:
How long can the chemical compound be stable in DMEM at 4 °C?
Answer:
The compound is stable in DMEM at 4 degree for one week.

PARP Signaling Pathway Map

PARP Inhibitors with Unique Features

Selective PARP Inhibitors

AG-14361 : PARP1-selective, K_i<5 nM.
Selective PARP Inhibitors

UPF 1069 : PARP2-selective, IC50=0.3 μM.
Most Potent PARP Inhibitor

MK-4827 (Niraparib) : PARP1, IC50=3.8 nM; PARP2, IC50=2.1 nM.
PARP Inhibitor in Clinical Trial

Iniparib (BSI-201) : Phase III for solid tumors.
Newest PARP Inhibitor

BMN 673 : Novel PARP inhibitor with IC50 of 0.58 nM. Also a potent inhibitor of PARP-2, but does not inhibit PARG and highly sensitive to PTEN mutation.

Related PARP Products

G007-LK ^New

G007-LK is a potent and selective tankyrase inhibitor with IC50 of 46 nM and 25 nM for TNKS1/2, respectively.
NU1025 ^New

NU1025 is a potent PARP inhibitor with IC50 of 400 nM.
SCR7 ^New

SCR7 is a specific DNA Ligase IV inhibitor, which blocks nonhomologous end-joining (NHEJ). It increases the efficiency of HDR-mediated genome editing up to 19-fold using CRISPR/Cas9 in mammalian cells and mouse embryos.
Veliparib (ABT-888)

Veliparib (ABT-888) is a potent inhibitor of PARP1 and PARP2 with K_i of 5.2 nM and 2.9 nM in cell-free assays, respectively. It is inactive to SIRT2. Phase 3.

Features:Increases the efficacy of common cancer therapies such as radiation and alkylating agents.
Rucaparib (AG-014699,PF-01367338) phosphate

Rucaparib (AG-014699, PF-01367338) is an inhibitor of PARP with K_i of 1.4 nM for PARP1 in a cell-free assay, also showing binding affinity to eight other PARP domains. Phase 3.

Features:The first PARP inhibitor used in clinical trials combined with temozolomide.
Talazoparib (BMN 673)

Talazoparib (BMN 673) is a novel PARP inhibitor with IC50 of 0.57 nM for PARP1 in a cell-free assay. It is also a potent inhibitor of PARP-2, but does not inhibit PARG and is highly sensitive to PTEN mutation. Phase 3.

Features:Most potent and selective PARPi reported thus far.
Iniparib (BSI-201)

Iniparib (BSI-201) is a PARP1 inhibitor with demonstrated effectiveness in triple-negative breast cancer (TNBC). Phase 3.
PJ34 HCl

PJ34 HCl is the hydrochloride salt of PJ34, which is a PARP inhibitor with EC50 of 20 nM and is equally potent to PARP1/2.

Features:Water-soluble PARP1/2 inhibitor with >10,000-fold potentcy vs. 3-aminobenzamide (prototypical PARP inhibitor). Potential uses in cardiovascular diseases (stroke, cerebral ischemia, & myocardial ischemia).
AG-14361

AG14361 is a potent inhibitor of PARP1 with K_i of <5 nM in a cell-free assay. It is at least 1000-fold more potent than the benzamides.

Features:The 1st high-potency PARP-1 inhibitor with the specificity & in vivo activity to enhance chemotherapy and radiation therapy of human cancers.
A-966492

A-966492 is a novel and potent inhibitor of PARP1 and PARP2 with K_i of 1 nM and 1.5 nM, respectively.

Features:A promising, structurally diverse benzimidazole analogue that is being further characterized preclinically.

Choose Your Country or Region

By Signaling Pathways

By product type

Olaparib (AZD2281, Ku-0059436)

Cited by 349 Publications

Purity & Quality Control

Choose Selective PARP Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Olaparib (AZD2281, Ku-0059436) SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

Tech Support

Frequently Asked Questions

PARP Signaling Pathway Map

PARP Inhibitors with Unique Features

Related PARP Products

Choose Your Country or Region

By Signaling Pathways

By product type

Olaparib (AZD2281, Ku-0059436)

Cited by 349 Publications

Purity & Quality Control

Choose Selective PARP Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Olaparib (AZD2281, Ku-0059436) SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

Tech Support

Frequently Asked Questions

PARP Signaling Pathway Map

PARP Inhibitors with Unique Features

Related PARP Products

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)